Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2020-12-01 Share Issue/Capital Cha…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Exercise of employee share options
Share Issue/Capital Change Classification · 99% confidence The document explicitly details the purchase of shares by primary insiders (CFO and VPs) following the exercise of employee share options. This transaction involves executives acquiring company stock, which directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for this activity is DIRS.
2020-12-01 English
Photocure ASA: Exercise of employee share options
Director's Dealing Classification · 99% confidence The document explicitly details the purchase of shares by primary insiders (CFO and VPs) following the exercise of employee share options. This transaction involves executives dealing in the company's stock. According to the definitions, 'Director's Dealing (Code: DIRS)' covers the 'Report of personal share transactions by company directors and executives (insider trades)'. The content perfectly matches this description, as it lists the number of shares purchased by specific insiders and their resulting holdings.
2020-12-01 English
Photocure ASA: Exercise of employee share options and share capital increase
Share Issue/Capital Change Classification · 98% confidence The document explicitly details the exercise of employee share options and the subsequent increase in share capital due to the issuance of new shares. This directly relates to changes in the company's capital structure and share count. The filing type definitions point to 'Capital/Financing Update (Code: CAP)' for updates on fundraising, financing activities, or capital structure changes. While it involves insider transactions (Directors' Dealing), the primary focus and consequence announced is the capital increase resulting from the option exercise, making CAP the most precise fit over DIRS or SHA, which are more focused on general share issues or insider trades without the capital structure change context. Given the nature of the announcement, it is a direct update on financing/capital structure, not just a report announcement (RPA/RNS).
2020-11-30 English
Photocure ASA: Exercise of employee share options and share capital increase
Capital/Financing Update Classification · 98% confidence The document explicitly announces the exercise of employee share options and the resulting increase in the company's share capital by issuing new shares. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves insider transactions (DIRS), the primary focus and action announced is the capital increase resulting from the option exercise, making CAP the most precise fit. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a Director's Dealing report (DIRS) which focuses only on the transaction by insiders, whereas this focuses on the corporate action (capital increase).
2020-11-30 English
Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702 (Cevira)
Earnings Release Classification · 95% confidence The document is a press release announcing a significant event in a clinical trial (first patient administration in Phase III) and the triggering of a milestone payment between Photocure ASA and its partner Asieris. This type of announcement, focusing on operational progress, clinical milestones, and associated financial triggers (milestone payments), is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a formal announcement of key operational and financial news outside of a mandated periodic report (like 10-K or IR), and it is not a transcript (CT), a presentation (IP), or a specific regulatory filing like DIRS or DIV, the most appropriate classification is Earnings Release (ER), as these releases often contain the most timely operational highlights that drive investor interest, even if they aren't the full quarterly report. Q4 2020
2020-11-11 English
Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702 (Cevira)
Regulatory Filings Classification · 100% confidence The document is a press release announcing a significant event in a clinical trial (First Patient Administration in Phase III) and the triggering of a milestone payment between Photocure ASA and its partner Asieris. This type of announcement, detailing operational progress, clinical updates, and associated financial milestones, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational/clinical update rather than a summary of overall financial performance (ER) or a general regulatory notice, and it doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP), it most closely aligns with a general announcement. Given the context of corporate reporting, this is a standard press release announcing corporate/clinical progress. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). It is best classified as a Regulatory Filing (RNS) as a general announcement, although if 'ER' were interpreted broadly to include operational highlights, it could fit there too. However, RNS serves as the best general regulatory announcement fallback for specific operational news that isn't a formal financial report.
2020-11-11 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.